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Abstract
Background: Tuberculosis (TB) and serious bloodstream infections (BSI) may contribute to the high early mortality observed
among patients qualifying for antiretroviral therapy (ART) with unexplained weight loss, chronic fever or chronic diarrhea.
Methods and Findings: A prospective cohort study determined the prevalence of undiagnosed TB or BSI among
ambulatory HIV-infected adults with unexplained weight loss and/or chronic fever, or diarrhea in two routine program
settings in Malawi. Subjects with positive expectorated sputum smears for AFB were excluded. Investigations Bacterial and
mycobacterial blood cultures, cryptococcal antigen test (CrAg), induced sputum (IS) for TB microscopy and solid culture, full
blood count and CD4 lymphocyte count. Among 469 subjects, 52 (11%) had microbiological evidence of TB; 50 (11%) had
a positive (non-TB) blood culture and/or positive CrAg. Sixty-five additional TB cases were diagnosed on clinical and
radiological grounds. Nontyphoidal Salmonellae (NTS) were the most common blood culture pathogens (29 cases; 6% of
participants and 52% of bloodstream isolates). Multivariate analysis of baseline clinical and hematological characteristics
found significant independent associations between oral candidiasis or lymphadenopathy and TB, marked CD4
lymphopenia and NTS infection, and severe anemia and either infection, but low positive likelihood ratios (,2 for all
combinations).
Conclusions: We observed a high prevalence of TB and serious BSI, particularly NTS, in a program cohort of chronically ill
HIV-infected outpatients. Baseline clinical and hematological characteristics were inadequate predictors of infection. HIV
clinics need better rapid screening tools for TB and BSI. Clinical trials to evaluate empiric TB or NTS treatment are required in
similar populations.
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Introduction
Mortality among patients initiating antiretroviral therapy (ART)
in low-income settings is greater than in high-income settings,
particularly within the first 3–12 months of treatment [1–3]. This
is especially true among patients presenting with unexplained
weight loss, chronic fever or chronic diarrhea [2,4–6].
Weight loss and fever among HIV-infected persons often reflect
active tuberculosis (TB) and other serious bloodstream infections
(BSI) [7–9]. Smear microscopy, the mainstay of diagnosis in these
settings, is highly specific, but has low sensitivity especially in HIV-
infected individuals [10,11]. Several studies have evaluated the
predictive value of various symptoms for the detection of TB [11–
15], with cough, weight loss, fever, and night sweats each
associated with active TB but with low specificity for culture-
confirmed TB.
Studies performed in a variety of sub-Saharan African settings
have shown that the most common BSI among HIV-infected
persons hospitalised with acute or chronic fever are Mycobacterium
tuberculosis, Cryptococcus neoformans, Streptococcus pneumoniae, nonty-
phoidal Salmonella (NTS) species, malaria and Staphylococcus aureus
[7–9,16–18]. These studies selected febrile patients who were ill
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enough to be admitted to hospital but it is not clear if their findings
can be generalized to a larger population of ambulatory patients
with a variety of non-specific symptoms of chronic illness.
Screening of asymptomatic patients for cryptococcal infection
have also demonstrated its presence among ambulatory HIV-
infected patients [16,17]. While several autopsy studies have
identified specific causes of death among HIV-infected persons
[19–22], they provide limited information about how to identify
patients at risk of TB or other infections.
In this study, our primary aim was to prospectively determine
the prevalence of TB and serious BSI among sputum smear
negative, HIV-infected persons presenting as out-patients in
a program setting with unexplained chronic fever and/or weight
loss and/or chronic diarrhea. Our second aim was to determine if
baseline clinical or hematological characteristics of this population
were associated with identification of a pathogen.
Methods
Study Design
This was a prospective observational cohort study. Subjects
were enrolled between February and November 2010.
Ethics
This study received prior ethical approval from the National
Health Sciences Research Committee of Malawi and from the
Ethics Advisory Group of the International Union Against
Tuberculosis and Lung Disease (IUATLD). Eligible patients
provided written informed consent.
Study Population
HIV-infected adults ($15 years of age) undergoing assessment
of eligibility for first-time initiation of antiretroviral therapy, or
seeking health care, in outpatient clinics at Zomba Central
Hospital and Thyolo District Hospital, serving 2 districts in the
southern region of Malawi with high HIV co-infection rates of
$70% among TB patients and adult HIV prevalence of 12%.
Patients were eligible for inclusion in the study if they had three
negative expectorated sputum smears (or if they were unable to
expectorate) and at least one of the following criteria: history of
unexplained severe weight loss, defined as .10% of baseline body
weight (estimated or documented); or unexplained chronic fever
(intermittent or continuous for .1 month duration); or un-
explained chronic diarrhea (loose or watery stools three or more
times daily) for .1 month duration; or unexplained moderate
weight loss, defined as ,10% of baseline body weight (estimated
or documented) with CD4 count ,250 cells/mL. Anti-TB therapy
in the past month or pregnancy were exclusion criteria.
Enrolment
Clinical officers involved in routine clinical care identified
potential participants and referred them to on-site study nurses.
Nurses were involved in study-related diagnostic procedures only
but not in clinical care. Diagnosis and treatment was provided by
non-study clinicians. (See Figure 1).
Procedures
A baseline interview included questions about demographics,
clinical history and current symptoms. Weight and height were
recorded, and venepuncture was performed.
Patients able to expectorate had sputum smear microscopy
either prior to referral to a study nurse, or during the screening
process. In either case, collection and examination of expectorated
sputum was performed by non-study program personnel at the two
enrolment sites. Malawi National TB Program guidelines stipulate
one spot sputum specimen, one early morning specimen and
another spot specimen when the morning specimen is submitted.
Sputum induction was carried out using nebulised, hypertonic
(5%) saline under recommended biosafety conditions [23,24] in an
open-air location 100metres away from other patients or staff; study
nurses wore N95 respirators during the procedure. If sputum
induction failed, participants were enrolled without a sputum
specimen. A chest radiograph was obtained if not already available.
Participants were then managed under the routine care system
at each hospital, but with the benefit of results provided by the
study team. Information on clinical TB diagnoses made after
enrolment and information on mortality was obtained from
routine program (non-study) sources, although the study employed
tracers to obtain some mortality data. Mortality and other
outcomes are the subject of a separate analysis and paper. The
enrolment process is shown in Figure 1.
Laboratory Methods & Procedures
TB microscopy and cultures were performed at the TB
laboratory of the College of Medicine/Malawi-Liverpool-Well-
come Trust Clinical Research Programme (MLW), Blantyre. This
laboratory provides TB diagnostic support to clinical trials funded
by the National Institutes of Health, Division of AIDS (NIH/
DAIDS)/AIDS Clinical Trials Group (ACTG) and as such
employs the quality management system recommended by the
NIH, including an annual audit. The laboratory takes part in the
External Quality Assurance programs of both the NIH and the
UK National External Quality Assurance Scheme (NEQAS).
After same-day transport to the laboratory, induced sputum (IS)
was decontaminated with an equal volume of 4% NaOH for
15 minutes and concentrated with centrifugation before culture
onto Lowenstein-Jensen (LJ) media for up to eight weeks. Smears
made from both direct and concentrated sputum were examined
under fluorescent microscopy (Auramine O), with any positive
results confirmed by Ziehl-Neelsen staining (ZN). Mycobacterial
isolates were further speciated asMycobacterium tuberculosis (MTB) or
nontuberculous mycobacteria (NTM) using microscopic cording
and MBP-64 lateral flow assays (CapiliaH; TAUNS Laboratories,
Inc., Numazu, Japan) and, if either test was negative, growth on
media with p-nitrobenzoic acid (PNB) at room temperature and/
or 45 deg C.
Blood for culture of mycobacteria and other bacterial (or fungal)
pathogens was collected using a sterile technique and transferred
the same day to the Microbiology Laboratory at Queen Elizabeth
Hospital, Blantyre (supported by the Malawi-Liverpool-Wellcome
Trust Clinical Research Programme). For bacterial culture,
venous blood (5–7.5 mL) was taken for aerobic culture in 50 mL
of broth and incubated for 7 days (BacT/ALERT 3DH;
bioMe´rieux SA, Marcy l’Etoile, France). Isolates were then
identified using standard diagnostic techniques [25]. For the
purpose of this study, all organisms which are found as normal skin
or oral flora were considered to be contaminants, including
coagulase-negative Staphylococci, alpha-hemolytic Streptococci other
than S. pneumoniae, and diphtheroids. Antibiotic susceptibility was
determined by disc testing (Oxoid, Cambridge, UK) [26].
For mycobacterial culture, venous blood (5 mL) was inoculated
into 50 mL broth (BACTEC Myco/F LyticH; Becton Dickinson
Microbiology Systems, Sparks, MD, USA) and incubated at
37 deg C. Bottles were inspected daily for the first 14 days and
then once every 2 days using a handheld UV Woods lamp.
Contents of bottles were concentrated by centrifugation (3000 g
for 15 minutes) either within 48 hours after first detection of
fluorescence, or at the end of 6 weeks incubation (whichever
TB and Bacteremia in ART Candidates
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occurred sooner). The concentrate was examined with ZN and
Gram’s staining to exclude bacterial contaminants, and sub-
cultured onto LJ media. ZN positive subcultures were then
speciated as above.
Cryptococcal antigen tests were conducted on a single 1:10
dilution of serum using a Cryptococcus rapid latex agglutination test
(Oxoid, Cambridge, UK).
CD4 counts were conducted on venous blood (CyFlowH; Partec
GmbH, Goerlitz, Germany), as were full blood counts (AutoRead
PlusH; QBC Diagnostics, Port Matilda, PA, USA).
Definitions of Tuberculosis and Blood Stream Infections
TB was defined as confirmed, probable or possible using the
following case-definitions: Confirmed TB: one or more colonies of
MTB on culture of IS or blood. Probable TB: one or more acid-fast
bacilli on smear microscopy from IS despite negative cultures if
smears were confirmed as ZN positive on review by 3 independent
readers. Possible TB: compatible clinical and/or radiographic
findings with decision to treat for TB made by treating clinical
officers; includes enrolled subjects who started TB treatment up to
3 months after study enrolment (confirmed through TB registers).
NTM disease was defined as disseminated NTM disease if there was
isolation from blood of nontuberculous mycobacteria (NTM). The
diagnosis of NTM lung disease was not possible in this study
because only one sputum culture was taken per participant.
Sputum NTM isolates were therefore of uncertain clinical
significance. [27] We had no means for further speciation of
NTM isolates.
Figure 1. Study Enrolment Flowchart.
doi:10.1371/journal.pone.0039347.g001
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BSI were defined as isolation of pathogenic bacteria or fungal
organism (non-pathogenic species as defined in Methods were
excluded) or a positive serum cryptococcal antigen titre of $1:10
(in general a titre of $1:8 is considered indicative of disseminated
cryptococcal infection but the assay used in this study provided
only a single titre of 1:10; positives at this dilution were considered
cases but higher dilutions of serum were not tested).
Statistical Analysis
Data and statistical analysis were conducted using IBM SPSS
Statistics 19 (IBM, Armonk, NY, USA). Baseline characteristics
were described with proportions or medians (interquartile ranges
[IQR]). Comparisons between groups were made using non-
parametric independent sample median tests. Poverty score (using
the household poverty assessment model for Malawi as described
by Payongayong et al. [28]) was categorized into quartiles. Body
Mass Index (BMI), CD4, Hb, WBC and platelets were categorized
using conventional cut-off values. Multivariate logistic regressions
models were fitted with ‘‘confirmed or probable TB’’ or ‘‘NTS’’ as
the outcome variable. A minimum of 7 events per variable was
required to include a predictor variable in a regression model.
Adjusted odds ratios (aORs) (95% CI) were calculated for each
model and were controlled for sex, age, poverty score, chronic
fever (present .1 month; intermittent or continuous), weight loss
.10%, chronic diarrhea (present 1 month or more), BMI, chronic
cough (2 weeks or more), presence of oral candidiasis, lymphade-
nopathy, CD4 count, Hb, WBC count and platelets. Positive
likelihood ratio was defined as [sensitivity/(1– specificity)];
negative likelihood ratio was defined as [(1– sensitivity)/specific-
ity]. A significance level of 0.05 was set for all statistical testing.
Results
Patient Characteristics
There were 469 subjects (279 females) enrolled in the study and
eligible for analysis, from February to December 2010, 285 at
Zomba Central Hospital and 184 at Thyolo District Hospital. (See
Table 1).
Study subjects were severely immunocompromised with a me-
dian CD4 count of 129 (IQR 49–216).
Among patients reporting severe weight loss (.10% of baseline
body weight), moderate weight loss (,10% of baseline body
weight) and no weight loss, the median BMI was 16.4 (IQR 15.3–
17.5), 17.9 (IQR 16.9–19.5) and 18.7 (IQR 16.8–20.0), re-
spectively, (p = 0.001 for differences between all groups).
Diagnosis of Tuberculosis and Bloodstream Infections
Tuberculosis. TB diagnosis was confirmed (IS or blood
culture-positive) in 48 and probable (IS smear-positive but culture
negative) in 4. IS cultures (46 positive) had a higher yield for MTB
than blood (11 positives, of which only 2 were from IS culture-
negative participants). IS specimens were smear-positive in 24/46
of the patients with IS culture-positive confirmed MTB. There
were an additional 65 possible TB cases based on clinical and/or
radiographic features (56% of total TB diagnoses).
Bloodstream infections. A total of 46 patients had other
BSI, with the most frequent pathogens being NTS (29 patients,
6.2% participants), other gram negative bacteria (9 patients, 1.9%:
5 Escherichia coli; 1 Acinetobacter baumannii, 1 Enterobacter sakazakii, 1
Citrobacter braakii, 1 Shigella dysenteriae) and 8 Cryptococcus (all antigen
titre $1:10) of whom 5 also had blood cultures positive for
Cryptococcus neoformans. A further 4 participants had disseminated
NTM disease (blood culture isolate), with 10 other NTM isolates
from sputum of undetermined significance. (See Table 2).
Overall there were 167 patients with a diagnosis of confirmed,
probable or possible TB, or a BSI (including NTM). No patient
had more than one laboratory-identified pathogen, although 10
possible TB cases were diagnosed among patients with bacteremia
(n = 8, of which 7 were NTS) or cryptococcal infection (n= 2).
Among the total study cohort there were 62 (13.2%) deaths
recorded within 3 months of study enrolment despite the
additional diagnostic information provided to clinicians through
this study. These deaths occurred in 12/48 confirmed TB cases,
5/65 possible TB cases, 5/29 NTS cases, 2/4 NTM blood culture
positive cases, 2/10 NTM IS culture positive cases, 1 cryptococcal
infection case and 35/302 subjects with no infection diagnosed.
Associations between Patient Characteristics and
Pathogens
Associations between patient characteristics and laboratory
identification of pathogens are shown in Table 3.
Multivariate analysis of all study subjects showed that only the
presence of oral candidiasis, or lymphadenopathy or severe
anemia (hemoglobin ,80 g/L for women or ,90 g/L for men)
were independently associated with confirmed or probable TB.
CD4 count was not associated with a diagnosis of TB.
Multivariate analysis showed that marked CD4 lymphopenia
(CD4,50 cells/mL) and severe anemia (as defined above) were
each independently associated with NTS BSI (median CD4
among patients with NTS infection was 46 cells/mL).
Modeling was performed to estimate the sensitivity, specificity
and positive and negative likelihood ratios for various combina-
tions of risk factors (fever, oral candidiasis, lymphadenopathy,
CD4 lymphopenia, anemia, thrombocytopenia) for confirmed/
probable TB and for NTS infection. No combination yielded
a positive likelihood ratio of .1.21 for TB or .1.68 for NTS
infection (see Table 4).
Discussion
This study shows that TB and NTS were the most commonly
identified causes of chronic fever and/or weight loss in smear-
negative, HIV-infected outpatients eligible for ART. Serious
infections were diagnosed in a third of study participants.
The majority of infections (117/167; 70%) were TB (confirmed,
probable and possible cases). A previous study from Malawi of 352
patients classified as smear-negative pulmonary TB found that
39% could be confirmed microbiologically, an equal proportion
had clinical and radiological findings compatible with TB but no
microbiological confirmation, and that 22% had non-TB di-
agnoses [29].
Among confirmed and probable TB infections, about half (28/
52; 54%) could have been diagnosed with smear microscopy of
concentrated IS alone. An additional 24/52 required culture of IS.
It has been demonstrated elsewhere that repeated sputum
induction can substantially improve the diagnostic yield of this
technique [23,24]. Although 11 cases had positive mycobacterial
blood cultures, only 2 required this for diagnosis after smear and
culture of IS. Monkongdee et al also found a low yield of
mycobacterial blood cultures among an outpatient population
[30].
Even enhanced sputum smear microscopy and culture cannot
entirely overcome the difficulty we encountered in diagnosing
active TB. Overall, 56% of TB cases were possible diagnoses
without microbiological evidence to support them. These cases are
likely to be a mixture of true TB cases not detected by IS or blood
cultures (see Limitations below) and other non-TB diagnoses
TB and Bacteremia in ART Candidates
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which may include other undiagnosed infections or HIV-related
malignancies.
The high prevalence of TB observed here is consistent with
several studies evaluating causes of morbidity and mortality among
HIV-infected patients in sub-Saharan Africa [19,20]. A study from
Abidjan, Cote d’Ivoire found a direct correlation between TB and
the degree of wasting at autopsy (44% among those with severe
wasting) [22]. Cox et al reviewed 20 autopsy series from sub-
Saharan Africa and found that TB was responsible for half of the
deaths among HIV-infected adults [21].
The surprising finding of our study was the high rate of NTS
infection among chronically unwell HIV positive patients, the
majority of whom were being treated as out-patients. NTS
bloodstream infection accounted for 17% of total cases (including
possible TB cases), and half of all blood cultures positive for
bacterial, mycobacterial or fungal pathogens. Gordon et al have
previously shown that the bacterial load of NTS in blood is low
[31] and our consistent use, in this study, of large inoculums of
blood may have contributed to the high diagnostic yield.
Invasive NTS are the commonest blood stream bacterial isolates
from febrile adult hospital admissions in HIV-prevalent areas of
Africa [18,31–33]. However, they have not been described in non-
acute admissions/out-patients, raising the possibility that they are
a cause of chronic infection in this population group. Recent
studies have shown that epidemic invasive NTS in Malawi is
caused by a novel host-restricted Salmonella typhimurium sequence
type (ST313) [34]. Further work is, therefore, required to
determine if the NTS isolates we have found in chronic disease
are the same genotype as those responsible for infection in acutely
unwell, HIV positive patients.
The spectrum of BSI observed in this population of ambulatory
chronically ill, HIV-infected patients in a program (non-academic)
setting differed from that observed in previous studies of acutely ill,
febrile, inpatients among whom Streptococcus pneumoniae was an
important cause of bacteremia [7,9,18,31,33,35]. Immediate
inoculation into blood culture bottles, installation onto the blood
culture machine an average of 4–6 hours post-collection, and
consistently high blood inoculum volumes ensured that contami-
nants were kept to a minimum (10%) and increased the likelihood
of culturing S. pneumoniae [36]. Our study enrolment period
encompassed wet and dry seasons in Malawi so seasonal variation
[8] does not explain the absence of S. pneumoniae that we observed.
Instead, this may be a true difference in the spectrum of HIV-
related BSIs between hospitalised patients and out-patients.
In this study population, microbiological evidence of TB was
significantly associated with the presence of oral candidiasis or
lymphadenopathy or anemia. Were et al also found an association
with lymphadenopathy [15].
Table 1. Enrolment characteristics of 469 study subjects.
Characteristic N (%) or Median (IQR)
Sex F 279 (58%)
Age (median; IQR) 36 (24–48)
Below national poverty line 233 (49.7%)
Fever, chronic* 294 (62.7%)
Weight loss, severe*(.10% body wt) 249 (53.1%)
Weight loss, moderate*(,10% body wt) 209 (44.6%)
Diarrhea, chronic* 165 (35.2%)
More than one symptom defined as inclusion criteria** 320 (68.2%)
BMI, kg/m2 (median; IQR) 17.1 (15.9–18.4)
Cough, chronic 284 (60.6%)
Oral Candidiasis 160 (34.1%)
Lymphadenopathy (any) 180 (38.4%)
CD4, cells/mL (median; IQR) 129 (49–216)
Hemoglobin, male, g/L (median; IQR) 100 (84–115)
Hemoglobin, female, g/L (median; IQR) 100 (82–115)
WBC, X109/L (median; IQR) 5.4 (4.0–7.5)
Platelets, X109/L (median; IQR) 235 (159–313)
*See Methods for definitions of inclusion criteria.
**Chronic fever, severe weight loss, chronic diarrhea, moderate weight loss plus CD4,250 cells/mL.
doi:10.1371/journal.pone.0039347.t001
Table 2. Infections diagnosed among 469 study subjects.
Infection Number (%)
Confirmed Tuberculosis* 48 (10.2%)
Probable Tuberculosis* 4 (0.9%)
Possible Tuberculosis* 65 (13.9%)
Total Tuberculosis cases 117 (24.9%)
Nontuberculous mycobacterial disease 4 (0.9%)
Nontyphoidal salmonella species 29 (6.2%)
E.coli 5 (1.1%)
Other bacterial pathogens 4 (0.9%)
Cryptococcosis 8 (1.7%)
Total Bloodstream Infections 50 (10.7%)
Total All Infections 167/469 (35.6%)
*See Methods for case definitions.
doi:10.1371/journal.pone.0039347.t002
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Previously published studies have found cough to be associated
with the diagnosis of TB [12,13,15] but in this study of subjects
selected on the basis of negative expectorated sputum smears, as
well as fever and/or weight loss, cough was not a useful
discriminator.
Hemoglobin measurements are not routinely performed on
patients eligible for ART in Malawi. Our systematic determination
of Hemoglobin allowed us to examine the utility of Hemoglobin in
risk assessments of patients like those recruited into this study.
Most patients had some degree of anemia, with median
hemoglobin among study subjects being, respectively, 100 g/L
(IQR 84–115) for men and 100 g/L (IQR 82–115) for women.
Hemoglobin values below the median were significantly associated
with both TB, and NTS infection. Saathoff et al found HIV-TB
co-infection to be strongly associated with hemoglobin levels and
with severe anemia (Hemoglobin ,85) [37]. In that study,
conducted in Dar es Salaam, Tanzania, the prevalence of severe
anemia among co-infected women was 43.4%.
Our analysis shows that although it is possible to define a highly
sensitive predictor for the presence of active TB or NTS infection
derived from a combination of baseline clinical and/or hemato-
logical characteristics, even moderate specificity could only be
gained by compromising sensitivity considerably.
Limitations of the Study
Our use of solid culture media for a single IS culture is likely to
have resulted in an underestimation of the true burden of TB and
NTM disease. A study by Monkongdee et al evaluated the yield of
acid-fast smear and Mycobacterial cultures. In that study a single
solid (LJ) culture detected only 47.6% of the infections detected by
three liquid cultures (Mycobacterial Growth Indicator Tube). [30]
This could have resulted in patients being misclassified as not TB
or possible TB when they would have been confirmed TB with
fully optimized TB culture; associations are likely to have been
diluted through this misclassification.
We did not evaluate patients for malaria. In a hospital-based
study of febrile patients in Malawi, 75/233 (32.2%) had chronic
fever (.1 month duration); the remainder had acute fever. Among
the entire group the prevalence of malaria parasitemia was 4%
which was not significantly different than the prevalence among
a control group of healthy afebrile adults (7%) [7,8].
Conclusions
The high prevalence of TB and BSI in this population of
chronically ill patients, with no clear features to allow the different
pathogens to be distinguished clinically, has important diagnostic
and therapeutic implications. First, our results highlight the
importance of TB and the difficulty in excluding TB in this
patient group and, secondly, our results also raise the need to
consider NTS in outpatient ART clinics. New rapid TB
diagnostics now exist with the potential to increase the sensitivity
of diagnosis [38,39] but are unlikely to be widely available at
primary care level in resource-limited settings such as Malawi for
the foreseeable future. Even if Xpert MTB/RIF were available for
testing of smear negative sputum specimens, 28–57% [38,40] of
pulmonary TB infections would be missed unless more than one
specimen were tested per patient, with concomitant cost increases.
Extrapulmonary TB would not be detected. Sputum induction
offers the potential to increase TB case detection by increasing the
sensitivity of sputum smear microscopy. Although serum crypto-
coccal antigen testing could identify most cases of disseminated
cryptococcal disease, this infection was diagnosed in less than 2%
of this cohort. There are no specific rapid diagnostic tests for the
other serious BSI documented here.
Our results suggest a possible role for more aggressive use of
presumptive treatment for disseminated infections among high
risk patients such as those enrolled in this study. Trials to evaluate
empiric TB treatment for high risk HIV-infected patients have
been carefully considered and advocated previously [41] and are
ongoing. Although autopsy studies provide information about
causes of death, they are less helpful in identifying who is at risk of
death. It is uncertain to what extent findings from studies of
hospitalized patients can be generalized to chronically ill
ambulatory patients. In contrast, this prospective study of
ambulatory patients enrolled from routine HIV treatment
programs has shown that a readily identifiable, high risk group
of patients can be defined using any of the inclusion criteria for
this study. This bolsters the argument for trials of empiric TB
treatment among such patients. Further research should be
undertaken to confirm the high prevalence of bloodstream
Table 3. Associations of baseline characteristics with
laboratory-diagnosed TB or NTS infections: Multivariate
analysis.
All subjects TB (conf/prob) NTS
n=469 n=52 n=29
Sex, F 0.67 (0.34–1.33) 0.96 (0.42–2.22)
Age 0.98 (0.95–1.02) 0.98 (0.93–1.02)
Poverty (LQ*) 1.11 (0.51–2.43) **
Fever, chronic 1.19 (0.56–2.51) 1.43 (0.54–3.76)
Weight loss .10% 1.82 (0.87–3.78) 1.01 (0.42–2.43)
Diarrhea, chronic 0.66 (0.31–1.41) 0.79 (0.29–2.12)
Cough, chronic 1.28 (0.61–2.70) 0.82 (0.31–2.18)
Oral Candidiasis 5.02 (1.48–17.01) 0.99 (0.99–1.01)
Lymphadenopathy 4.27 (1.35–13.56) 0.99 (0.99–1.01)
Wasting: BMI strata (kg/m2)
Severe; BMI,16.0 0.97 (0.43–2.23) 0.92 (0.34–2.47)
Moderate; BMI 16.0–16.99 0.82 (0.35–1.96) **
Mild or no; BMI.17.0 1 **
CD4 strata (cells/mL)
CD4,50 1.01 (0.40–2.53) 4.00 (1.70–9.42)
CD4 50–199 1.09 (0.50–2.38) **
CD4$200 1 **
Anemia (defined below)
Severe anemia 3.44 (1.29–9.20) 2.09 (1.00–5.06)
Moderate anemia 1.82 (0.72–4.57) **
Mild anemia or no anemia 1 **
Platelets (X109/L)
Platelets ,50,000 1.03 (0.19–5.53) **
Platelets 50,000–149,000 0.56 (0.22–1.39) 1.83 (0.72–4.68)
Platelets $150,000 1 1
WBC .8.0 (X109/L)*** 0.84 (0.37–1.89) 0.85 (0.27–2.75)
Severe anemia: Hemoglobin ,80 g/L (F) & ,90 g/L (M).
Moderate anemia: Hemoglobin 80–109 g/L (F) & 90–119 g/L (M).
Mild or no anemia: $110 g/L (F) & $120 g/L (M).
*LQ = Lowest quartile; compared to remainder.
**There were too few cases with these characteristics to include in the
regression model.
***There were also no significant associations with WBC ,2.0 X109/L or WBC
.10.0 X109/L.
doi:10.1371/journal.pone.0039347.t003
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infections found in our study population. Presumptive antimicro-
bial treatment for these infections, including NTS infection, could
also be evaluated in clinical trials particularly for patients with
very low CD4 counts. Specific antimicrobial choices for such trials
will depend on whether TB is co-treated simultaneously or not,
since agents such as fluoroquinolones are active against both NTS
and TB.
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